SEP
SUPN icon

Signature Equity Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Signature Equity Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$775 Sell
15
-105
-88% -$5.35K ﹤0.01% 1310
2025
Q4 		$5.96K Buy
+120
New +$5.83K ﹤0.01% 944

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Signature Equity Partners's SUPN Position: Q1 2026 in Review

Signature Equity Partners reduced its Supernus Pharmaceuticals (SUPN) stake by 88% in Q1 2026, selling an estimated $5.35K and leaving 15 shares worth $775. The position accounts for ﹤0.01% of the portfolio, ranked #1310.

Signature Equity Partners first reported a position in SUPN in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.96K in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Signature Equity Partners held 15 shares of Supernus Pharmaceuticals worth $775 as of Q1 2026.
  • Signature Equity Partners sold 105 Supernus Pharmaceuticals shares in Q1 2026, an estimated $5.35K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Signature Equity Partners's portfolio in Q1 2026, its #1310 holding.
  • Signature Equity Partners first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Signature Equity Partners's Supernus Pharmaceuticals position peaked at $5.96K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.